Publications by authors named "Mohammad S Siddqui"
Background And Aims: Obeticholic acid (OCA) is a farnesoid X receptor agonist used in primary biliary cholangitis (PBC) treatment. Recent studies have expanded OCA use for NASH treatment and results from phase 3 clinical trial have shown beneficial reduction of ≥1 stage of fibrosis with no NASH worsening. However, safety concerns still preside, thus we systematically examine the safety profile of OCA in chronic liver disease.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic syndrome (MetS) affects over one third of US adults and is linked to non-alcoholic fatty liver disease (NAFLD), which isn't currently included in its traditional diagnosis.
- A study analyzed data from over 46,000 individuals to see if including NAFLD in the MetS criteria (referred to as MetS2) improved the accuracy of identifying those with metabolic issues and predicting health risks.
- The findings showed that MetS2 identified an additional 8% of individuals with metabolic risk and was significantly associated with higher all-cause and cardiovascular disease mortality, highlighting the importance of early intervention.